168 related articles for article (PubMed ID: 38455062)
1. Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.
Kared H; Jyssum I; Alirezaylavasani A; Egner IM; The Tran T; Tietze L; Lund KP; Tveter AT; Provan SA; Ørbo H; Haavardsholm EA; Vaage JT; Jørgensen K; Syversen SW; Lund-Johansen F; Goll GL; Munthe LA
Front Immunol; 2024; 15():1296273. PubMed ID: 38455062
[TBL] [Abstract][Full Text] [Related]
2. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
[TBL] [Abstract][Full Text] [Related]
3. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
5. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Jyssum I; Kared H; Tran TT; Tveter AT; Provan SA; Sexton J; Jørgensen KK; Jahnsen J; Kro GB; Warren DJ; Vaage EB; Kvien TK; Nissen-Meyer LH; Anderson AM; Grødeland G; Haavardsholm EA; Vaage JT; Mjaaland S; Syversen SW; Lund-Johansen F; Munthe LA; Goll GL
Lancet Rheumatol; 2022 Mar; 4(3):e177-e187. PubMed ID: 34977602
[TBL] [Abstract][Full Text] [Related]
6. Persistent but atypical germinal center reaction among 3
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Meisel C; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
Front Immunol; 2022; 13():943476. PubMed ID: 36032111
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab.
Tolf A; Wiberg A; Müller M; Nazir FH; Pavlovic I; Laurén I; Mangsbo S; Burman J
JAMA Netw Open; 2022 May; 5(5):e2211497. PubMed ID: 35544139
[TBL] [Abstract][Full Text] [Related]
8. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
[TBL] [Abstract][Full Text] [Related]
9. Waning humoral immunity of SARS-CoV-2 vaccination in a rheumatoid arthritis cohort and the benefits of a vaccine booster dose.
Le Moine C; Soyfoo MS; Mekkaoui L; Dahma H; Tant L
Clin Exp Rheumatol; 2023 Jan; 41(1):82-87. PubMed ID: 35699073
[TBL] [Abstract][Full Text] [Related]
10. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
Isnardi CA; Cerda OL; Landi M; Cruces L; Schneeberger EE; Montoro CC; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; de Los Ángeles Correa M; Rosemffet MG; Abarza VC; Pellet SC; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; Quintana R; de la Vega MC; Kreplak N; Pifano M; Maid P; Pons-Estel GJ; Citera G
J Rheumatol; 2022 Dec; 49(12):1385-1389. PubMed ID: 36182107
[TBL] [Abstract][Full Text] [Related]
11. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis.
Limoges MA; Lortie A; Demontier É; Quenum AJI; Lessard F; Drouin Z; Carrier N; Nguimbus LM; Beaulieu MC; Boire G; Piché A; Allard-Chamard H; Ramanathan S; Roux S
J Leukoc Biol; 2023 Sep; 114(4):358-367. PubMed ID: 37478373
[TBL] [Abstract][Full Text] [Related]
14. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
Front Immunol; 2022; 13():960001. PubMed ID: 36311767
[TBL] [Abstract][Full Text] [Related]
16. Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination.
Bondareva M; Letz P; Karberg K; Schrezenmeier E; Semin I; Rincon-Arevalo H; Dörner T; Mashreghi MF; Stefanski AL; Kruglov AA
J Autoimmun; 2022 Dec; 133():102918. PubMed ID: 36228431
[TBL] [Abstract][Full Text] [Related]
17. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study.
Farroni C; Aiello A; Picchianti-Diamanti A; Laganà B; Petruccioli E; Agrati C; Garbuglia AR; Meschi S; Lapa D; Cuzzi G; Petrone L; Vanini V; Salmi A; Altera AMG; Repele F; Grassi G; Bettini A; Vita S; Mariano A; Damiani A; Infantino M; Grossi V; Manfredi M; Niccoli L; Puro V; Rosa RD; Salemi S; Sesti G; Scolieri P; Bruzzese V; Benucci M; Cantini F; Nicastri E; Goletti D
Int J Infect Dis; 2022 Dec; 125():195-208. PubMed ID: 36328289
[TBL] [Abstract][Full Text] [Related]
18. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
19. Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
Benucci M; Damiani A; Gobbi FL; Lari B; Grossi V; Infantino M; Manfredi M
Immunol Res; 2022 Aug; 70(4):493-500. PubMed ID: 35543863
[TBL] [Abstract][Full Text] [Related]
20. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.
Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F
Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
